These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 27987649)

  • 1. Cost-Effectiveness of a National Opportunistic Screening Program for Atrial Fibrillation in Ireland.
    Moran PS; Teljeur C; Harrington P; Smith SM; Smyth B; Harbison J; Normand C; Ryan M
    Value Health; 2016 Dec; 19(8):985-995. PubMed ID: 27987649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study.
    Hobbs FD; Fitzmaurice DA; Mant J; Murray E; Jowett S; Bryan S; Raftery J; Davies M; Lip G
    Health Technol Assess; 2005 Oct; 9(40):iii-iv, ix-x, 1-74. PubMed ID: 16202350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of screening for atrial fibrillation in primary care with a handheld, single-lead electrocardiogram device in the Netherlands.
    Jacobs MS; Kaasenbrood F; Postma MJ; van Hulst M; Tieleman RG
    Europace; 2018 Jan; 20(1):12-18. PubMed ID: 27733465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening strategies for atrial fibrillation: a systematic review and cost-effectiveness analysis.
    Welton NJ; McAleenan A; Thom HH; Davies P; Hollingworth W; Higgins JP; Okoli G; Sterne JA; Feder G; Eaton D; Hingorani A; Fawsitt C; Lobban T; Bryden P; Richards A; Sofat R
    Health Technol Assess; 2017 May; 21(29):1-236. PubMed ID: 28629510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of a community-based screening programme for chronic atrial fibrillation in Japan.
    Maeda K; Shimbo T; Fukui T
    J Med Screen; 2004; 11(2):97-102. PubMed ID: 15153326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
    Chevalier J; Delaitre O; Hammès F; de Pouvourville G
    Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study.
    Lowres N; Neubeck L; Salkeld G; Krass I; McLachlan AJ; Redfern J; Bennett AA; Briffa T; Bauman A; Martinez C; Wallenhorst C; Lau JK; Brieger DB; Sy RW; Freedman SB
    Thromb Haemost; 2014 Jun; 111(6):1167-76. PubMed ID: 24687081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cost-effectiveness analysis of screening for silent atrial fibrillation after ischaemic stroke.
    Levin LÅ; Husberg M; Sobocinski PD; Kull VF; Friberg L; Rosenqvist M; Davidson T
    Europace; 2015 Feb; 17(2):207-14. PubMed ID: 25349228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia.
    Ademi Z; Pasupathi K; Liew D
    Eur J Prev Cardiol; 2015 Mar; 22(3):344-53. PubMed ID: 24281250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
    Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP
    Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-effectiveness of one-time opportunistic screening for atrial fibrillation in different age cohorts of inhabitants in Denmark aged 65 years and above: a Markov modelled analysis.
    Sciera LK; Frost L; Dybro L; Poulsen PB
    Eur Heart J Qual Care Clin Outcomes; 2022 Mar; 8(2):177-186. PubMed ID: 33337469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is Screening for Atrial Fibrillation in Canadian Family Practices Cost-Effective in Patients 65 Years and Older?
    Tarride JE; Quinn FR; Blackhouse G; Sandhu RK; Burke N; Gladstone DJ; Ivers NM; Dolovich L; Thornton A; Nakamya J; Ramasundarahettige C; Frydrych PA; Henein S; Ng K; Congdon V; Birtwhistle RV; Ward R; Healey JS
    Can J Cardiol; 2018 Nov; 34(11):1522-1525. PubMed ID: 30144961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.
    Lee S; Anglade MW; Meng J; Hagstrom K; Kluger J; Coleman CI
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):472-9. PubMed ID: 22740012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.
    Coleman CI; Straznitskas AD; Sobieraj DM; Kluger J; Anglade MW
    Am J Cardiol; 2012 Apr; 109(7):1020-5. PubMed ID: 22221944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.
    Kamel H; Johnston SC; Easton JD; Kim AS
    Stroke; 2012 Mar; 43(3):881-3. PubMed ID: 22308255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.
    Lee S; Anglade MW; Pham D; Pisacane R; Kluger J; Coleman CI
    Am J Cardiol; 2012 Sep; 110(6):845-51. PubMed ID: 22651881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of High-Dose Edoxaban Compared with Adjusted-Dose Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation Patients.
    Nguyen E; Egri F; Mearns ES; White CM; Coleman CI
    Pharmacotherapy; 2016 May; 36(5):488-95. PubMed ID: 27015873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness and screening performance of ECG handheld machine in a population screening programme: The Belgian Heart Rhythm Week screening programme.
    Proietti M; Farcomeni A; Goethals P; Scavee C; Vijgen J; Blankoff I; Vandekerckhove Y; Lip GY; Mairesse GH;
    Eur J Prev Cardiol; 2019 Jun; 26(9):964-972. PubMed ID: 30935219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain.
    González-Juanatey JR; Álvarez-Sabin J; Lobos JM; Martínez-Rubio A; Reverter JC; Oyagüez I; González-Rojas N; Becerra V
    Rev Esp Cardiol (Engl Ed); 2012 Oct; 65(10):901-10. PubMed ID: 22958943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation.
    O'Brien CL; Gage BF
    JAMA; 2005 Feb; 293(6):699-706. PubMed ID: 15701911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.